This is a demo store. No orders will be fulfilled.

SRT2104 (GSK2245840), NAD 依赖性去乙酰化酶 sirtuin 1 激活因子

SIRT1 选择性抑制剂 | 活化剂 | 调节剂
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
S413831-5mg
5mg 现货 Stock Image
S413831-25mg
25mg 期货 Stock Image
S413831-100mg
100mg 现货 Stock Image

基本描述

英文别名 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)- | DTXSID00648729 | NCGC00379071-01 | 1093403-33-8 | s7792 | Tazarotene- Bio-X | 5-thiazolecarboxamide,4-methyl-n-(2-(3-(4-morpholinylmethyl)im
规格或纯度 Moligand™, ≥98%
英文名称 SRT2104 (GSK2245840)
生化机理 SRT2104 (GSK2245840) 是一种参与能量平衡调节的选择性 SIRT1 激活剂。第二阶段
储存温度 -20°C储存
运输条件 超低温冰袋运输
作用类型 激活剂
作用机制 NAD 依赖性去乙酰化酶 sirtuin 1 激活因子
产品介绍


Information

SRT2104 (GSK2245840) is a selectiveSIRT1activator involved in the regulation of energy homeostasis. Phase 2.


Targets

SIRT1


In vitro

SRT2104 reduces p65/RelA acetylation levels in C2C12 cells.


In vivo

In male C57BL/6J mice, SRT2104 (100 mg/kg, p.o.) extends both mean and maximal lifespan of mice fed a standard diet, and enhances motor coordination, bone mineral density, and insulin sensitivity and decreased inflammation. Short-term SRT2104 treatment preserves bone and muscle mass in an experimental model of atrophy. In Male N171-82Q HD mice, SRT2104 (diet containing 0.5% SRT2104) effectively penetrates the blood-brain barrier, attenuates brain atrophy, improves motor function, and extends survival.


Cell Research(from reference)

Cell lines:C2C12 cell line 

Concentrations:3\xa0μM 

Incubation Time:24 h 

纯度 ≥98%

产品属性

ALogP 2.813
HBD Count 1
Rotatable Bond 6

关联靶点(人)

SIRT1 Tchem NAD 依赖性蛋白去乙酰化酶 sirtuin-1(NAD-dependent protein deacetylase sirtuin-1) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)

关联靶点(其它种属)

Hdac6 Histone deacetylase 6 (222 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
rep Replicase polyprotein 1ab (378 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SARS-CoV-2 (38078 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

PubChem SID 504769966
分子类型 小分子
IIUPAC Name 4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide
INCHI 1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
InChi Key LAMQVIQMVKWXOC-UHFFFAOYSA-N
Smiles CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6
Isomeric SMILES CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6
PubChem CID 25108829
分子量 516.64

化学和物理性质

溶解性 Solubility (25°C) In vitro DMSO: 5 mg/mL warmed with 50ºC Water: bath (9.67 mM); Water: Insoluble; Ethanol: Insoluble;
DMSO(mg / mL) Max Solubility 16
DMSO(mM) Max Solubility 30.96934035
Water(mg / mL) Max Solubility <1
分子量 516.600 g/mol
XLogP3 4.200
氢键供体数Hydrogen Bond Donor Count 1
氢键受体数Hydrogen Bond Acceptor Count 8
可旋转键计数Rotatable Bond Count 6
精确质量Exact Mass 516.14 Da
单同位素质量Monoisotopic Mass 516.14 Da
拓扑极表面积Topological Polar Surface Area 141.000 Ų
重原子数Heavy Atom Count 36
形式电荷Formal Charge 0
复杂度Complexity 758.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 0
未定义的原子立体中心计数Undefined Atom Stereocenter Count 0
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 1

安全和危险性(GHS)

象形图 GHS07
信号词 警告
危险声明

H302: 吞食有害

H315: 引起皮肤刺激

H319: 引起严重眼睛刺激

H335: 可能引起呼吸道刺激

预防措施声明

P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾

P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到2个结果

批号(Lot Number) 证书类型 货号
I2226062 分析证书 S413831
E2506244 分析证书 S413831

引用文献

1. Baksi A, Kraydashenko O, Zalevkaya A, Stets R, Elliott P, Haddad J, Hoffmann E, Vlasuk GP, Jacobson EW.  (2014)  A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes..  Br J Clin Pharmacol,  78  (1): (69-77).  [PMID:24446723]
2. Mercken EM, Mitchell SJ, Martin-Montalvo A, Minor RK, Almeida M, Gomes AP, Scheibye-Knudsen M, Palacios HH, Licata JJ, Zhang Y et al..  (2014)  SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass..  Aging Cell,  13  (5): (787-96).  [PMID:24931715]
3. Krueger JG, Suárez-Fariñas M, Cueto I, Khacherian A, Matheson R, Parish LC, Leonardi C, Shortino D, Gupta A, Haddad J et al..  (2015)  A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis..  PLoS ONE,  10  (11): (e0142081).  [PMID:26556603]
4. Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E.  (2016)  Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis..  Inflamm Bowel Dis,  22  (3): (607-14).  [PMID:26595549]
5. Jiang M, Zheng J, Peng Q, Hou Z, Zhang J, Mori S, Ellis JL, Vlasuk GP, Fries H, Suri V et al..  (2014)  Sirtuin 1 activator SRT2104 protects Huntington's disease mice..  Ann Clin Transl Neurol,  (12): (1047-52).  [PMID:25574479]

溶液计算器